Kathrin Meyer

Astrocytes from familial and sporadic ALS patients are toxic to motor neurons.

Transplantation of gene-corrected motor neurons as a therapeutic strategy for spinal muscular atrophy.

Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS.

Making sense of pain: are pluripotent stem cell-derived sensory neurons a new tool for studying pain mechanisms?

Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA - a dose response study in mice and nonhuman primates.

Glia-neuron interactions in neurological diseases: Testing non-cell autonomy in a dish.

Major histocompatibility complex class I molecules protect motor neurons from astrocyte-induced toxicity in amyotrophic lateral sclerosis.

The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy.

AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD.

Gene Therapy Corrects Brain and Behavioral Pathologies in CLN6-Batten Disease.

AAV9 Gene Therapy Increases Lifespan and Treats Pathological and Behavioral Abnormalities in a Mouse Model of CLN8-Batten Disease.

Intracranial delivery of AAV9 gene therapy partially prevents retinal degeneration and visual deficits in CLN6-Batten disease mice.